Skip to content

Study · In vitro (cells) · 2015

3 results

Thymosin α 1 potentiates the release by CD8(+) cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro.

Matteucci C, Minutolo A, Pollicita M, Balestrieri E, Grelli S, D'Ettorre G, Vullo V, Bucci I, Luchini A, Aquaro S, Sinibaldi-Vallebona P, Macchi B, Perno CF, Mastino A, Garaci E

Expert opinion on biological therapy22 Jun 2015Cited by 13 (Europe PMC)

PMID26094546 (opens in a new tab)DOI10.1517/14712598.2015.1021677 (opens in a new tab)PepBankPUB-26094546
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    Thymosin alpha‑1 potentiated the release, by LPS-stimulated CD8+ cells, of soluble factors that inhibited in vitro HIV-1 infection of macrophages and PBMCs.

    In plain wordsIn lab tests, thymosin alpha‑1 made immune CD8+ cells release factors that blocked HIV-1 infection of human cells.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseInhibition of in vitro HIV-1 infection of MDMs and PBMCs by CD8+ cell soluble factors
    Study

    humann: not reported in source

    LPS-stimulated CD8+ cells; human MDMs and PBMCs
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tα1 potentiates the release, in LPS-stimulated CD8(+) cells, of soluble factors able to inhibit both in vitro HIV-1 infection of MDMs and PBMCs and in vitro HTLV-1 infection of PBMCs.
    1 context sentence
    Summary · context
    Supernatants from lipopolysaccharide (LPS) stimulated CD8(+)-isolated cells treated with Tα1 were screened on in vitro infection of human monocyte-derived macrophages (MDMs) and PBMCs with HIV-1, and of PBMCs with human T lymphotropic virus 1 (HTLV-1).
  2. 02LabIn vitro (cells)Activity measurement

    Thymosin alpha‑1 potentiated the release, by LPS-stimulated CD8+ cells, of soluble factors that inhibited in vitro HTLV-1 infection of PBMCs.

    In plain wordsIn lab tests, thymosin alpha‑1 made immune CD8+ cells release factors that blocked HTLV-1 infection of human cells.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseInhibition of in vitro HTLV-1 infection of PBMCs by CD8+ cell soluble factors
    Study

    humann: not reported in source

    LPS-stimulated CD8+ cells; human MDMs and PBMCs
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tα1 potentiates the release, in LPS-stimulated CD8(+) cells, of soluble factors able to inhibit both in vitro HIV-1 infection of MDMs and PBMCs and in vitro HTLV-1 infection of PBMCs.
    1 context sentence
    Summary · context
    Supernatants from lipopolysaccharide (LPS) stimulated CD8(+)-isolated cells treated with Tα1 were screened on in vitro infection of human monocyte-derived macrophages (MDMs) and PBMCs with HIV-1, and of PBMCs with human T lymphotropic virus 1 (HTLV-1).
  3. 03LabIn vitro (cells)Mechanism

    Thymosin alpha‑1 induced a distinctive transcriptional profile in PBMCs from HIV-positive donors.

    In plain wordsIn lab tests, thymosin alpha‑1 caused a distinct pattern of gene activity in blood immune cells from HIV-positive donors.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableTranscriptional profile in PBMCs from HIV-positive donors
    Study

    humann: not reported in source

    PBMCs from HIV-positive donors
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A distinctive transcriptional profile was induced by Tα1 in PBMCs from HIV(+) donors.
    1 context sentence
    Summary · context
    Supernatants from lipopolysaccharide (LPS) stimulated CD8(+)-isolated cells treated with Tα1 were screened on in vitro infection of human monocyte-derived macrophages (MDMs) and PBMCs with HIV-1, and of PBMCs with human T lymphotropic virus 1 (HTLV-1).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.